Skip to main navigation Skip to search Skip to main content

Clozapine re-exposure after dilated cardiomyopathy

  • Clinical Pharmacy, Brocacef Ziekenhuisfarmacie, Maarssen, The Netherlands.
  • Altrecht Institute for Mental Health Care
  • Cardiology, Diakonessenhuis, Utrecht, The Netherlands.

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A 63-year-old woman with diabetes type II and a history of breast cancer was treated with clozapine for her refractory schizophrenia. She developed a dilated cardiomyopathy with an ejection fraction of 25%, a life-threatening event. The cause of heart failure could be multifactorial, with clozapine, family history, chemotherapy, diabetes type II and/or lithium as possible contributing risk factors. Clozapine was discontinued and the patient was referred to a hospice. Two weeks later, her heart failure slowly improved. Subsequently, she became extremely psychotic with a severe decline in quality of life. Therefore, it was decided to restart clozapine under cardiac monitoring. The patient's psychotic symptoms improved and her heart failure status remained stable for more than a year. Thereafter, a small deterioration was seen in cardiac function. In this case, re-exposure to clozapine was successful for at least 2 years.

Original languageEnglish
Article number219652
JournalBMJ Case Reports
Volume2017
DOIs
Publication statusPublished - 27 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Clozapine re-exposure after dilated cardiomyopathy'. Together they form a unique fingerprint.

Cite this